Pipeline

PIPELINE

NIT is currently conducting multiple clinical trials of NT-I7 as a monotherapy and in combination with leading immunotherapeutics such as checkpoint inhibitors, cancer vaccines, and more.

In addition, NIT is relentlessly conducting proof-of-concept animal studies in additional indications to further strengthen our pipeline and broaden the proof of applicability of NT-I7.

NT-I7 (rhIL-7-hyFc)

Development Stage
Preclinical Phase 1 Phase 2 Phase 3
ONCOLOGY
Monotherapy Single Dose – Glioblastoma (GBM) Ph1/pilot Learn more about the clinical trial
Multiple Doses1 – Glioblastoma (GBM) Ph1/2 Learn more about the clinical trial
Checkpoint Inhibitor Combinations Pembrolizumab2 - Triple Negative Breast Cancer (TNBC) Ph1b/2a Learn more about the clinical trial
Pembrolizumab3 – Solid Tumors (TNBC, NSCLC, SCLC, PanCA, MSS-CRC) Ph1b/2a  
Atezolizumab4 - High Risk Skin Cancers (MCC, cSCC, Melanoma) Ph1b/2a Learn more about the clinical trial
CAR-T Combinations  
INFECTIOUS DISEASES
Monotherapy Idiopathic CD4 Lymphocytopenia1,5
Adjuvant with Vaccines - Elderly Cancer Survivors Ph1/1b¹ Learn more about the clinical trial
ADDITIONAL DEVELOPMENT
Monotherapy Acute Radiation Syndrome
1. Investigator-initiated trial
2. Clinical Trial Collaboration with Genexine and Merck
3. Clinical Trial Collaboration with Merck. For more information, click HERE.
4. Clinical Trial Collaboration with Roche
5. Orphan Drug Designation in EU (2017. 05) and US (2019. 04)